

No	Theme	Paper Ref	First Name	Last Name	Country	Paper Title
001	Acute Liver Failure and Artificial Liver Support	A-02	Wenyu	Wu	China	Chemokine receptor CCR5 and its corresponding chemokine contributes to virus-induced liver injury via conventional NK cells recruitment
002		A-03	Smith	Kerdsin	Thailand	Factors associated with death and respiratory failure among patients with acute liver injury. Somdejprachaotaksin Maharaj Hospital, 2020
003		A-04	Hanisha	Khemani	Pakistan	Fulminant Hepatic Failure Etiology, Clinical Manifestations, and Outcome: An Experience of Tertiary Care Hospital of Karachi, Pakistan.
004		A-05	Smith	Kerdsin	Thailand	Risk factor and severity of acute liver injury between non-chronic liver disease and chronic liver disease
005		A-06	Siwaporn	Chainuvati	Thailand	Risk of the Development of Acute-on-Chronic Liver Failure and Overall Mortality among Nonalcoholic Steatohepatitis-related Cirrhosis Patients with Acute Decompensation
006		A-07	Thaninee	Prasoppokakorn	Thailand	Validation of Prognostic Scores to Predict Short-term Mortality in Acute-on-Chronic Liver Failure Among Patients with Hepatitis B infection: A Multicenter Study
007		A-09	Sakkarin	Chirapongsathorn	Thailand	Acute-on-Chronic Liver Failure: Epidemiology, Prognosis and Outcome in Thai population, multicenter study (ACLF-TM)
008		A-10	Kessarin	Thanapirom	Thailand	Comparing Four Prognostic Scores in Predicting Short-term Mortality of Patients with Acute-On-Chronic Liver Failure: a multi-center study
009	Alcoholic Liver Diseases: Clinical and Experimental	B-01	Tongluk	Teerasarntipan	Thailand	Clinical outcomes of acute decompensation and acute-on-chronic liver failure in patients with alcohol-related liver disease: a multi-center study
010		B-03	Do Seon	Song	South Korea	Rifaximin treatment in patients with severe alcoholic hepatitis; a multicenter, open-label, pilot randomized controlled trial
011		B-05	Wenyu	Wu	China	Up-regulation of Fgl2 induced by chronic ethanol consumption combined with HBV promotes hepatic macrophage M1-polarization and lipid metabolism disorder
012		B-06	Ajay	Duseja	India	Utility of point shear wave elastography done at Day 28 and Day 90 in prognosticating patients with alcohol related patients with Acute-on-chronic liver failure
013		B-07	Neeraj	Nagaich	India	WPSU (wellness programme for substance user) - for alcohol relapse prevention: A Ray of Hope in dark
014	Biliary Physiology, Transport, Cholangiocyte Biology, and Experimental Cholestasis	C-02	Natthaya	Chuaypen	Thailand	Proteomic Profiling of Liver Tissue Specimens identify Novel Phosphoproteins in Patients with Intrahepatic Cholangiocarcinoma
015	Cell and Molecular Biology	D-02	Filiz	Akyuz	Turkey	Could Cell-Free DNA And Methylations In RASSF1 And CDKN2AIP Genes Be New Biomarkers In The Diagnosis Of HCC? (Scientific)
016		D-03	Wirin	Bowonsomsarit	Thailand	Fried Mung Bean (Vigna Radiata) and Roasted Black Sesame (Sesamum Indicum) Supplement to Slow Down Diabetic Kidney and Fatty Liver
017	Cell and Molecular Biology	D-06	Stephanie	Johanes	Indonesia	Hematopoietic Stem Cells Therapy In Patients With End Stage Liver Disease: A Systematic Review Of Randomized Controlled Trial
018		D-07	Cheuk-Yan	Wong	Hong Kong	Role of lumican in the metastasis of hepatocellular carcinoma
019		D-09	Panas	Lertprapai	Thailand	A comparison of propofol and desflurane anesthesia on miRNA profiles after major hepatic resection in patients with hepatocellular carcinoma.
020		D-10	Wenyu	Wu	China	Fibrinogen-like protein 2 promotes fulminant hepatitis by inducing neutrophil activation and neutrophil extracellular traps formation

No	Theme	Paper Ref	First Name	Last Name	Country	Paper Title
021	Genomics and Precision Medicine	E-02	Dan	Duan	China	Influence Of TLR7 Polymorphism And Sex On Pharmacodynamic Response To TLR7 Agonist (RO7020531)
022		E-03	Aleksandr	Abramov	Russian Federation	Liver Cancer and Atherosclerosis are Interconnected through the MicroRNA
023		E-04	Pattapon	Kunadirek	Thailand	Profiling of cell-free DNA using Whole-exome sequencing in patients with Hepatocellular carcinoma in Thailand
024		E-05	Chih-Yang	Hsiao	Taiwan	The significance of quantified extracellular matrix features in patients with hepatocellular carcinoma after curative liver resection
025		E-06	Pattapon	Kunadirek	Thailand	Transcriptomic analyses reveal cancer-induce genes in PBMCs of Hepatocellular carcinoma for early diagnosis and prognosis
026		E-07	Wenyu	Wu	China	Transcriptomic Characterization Reveals Prognostic Molecular Signatures of Sorafenib Resistance in Hepatocellular Carcinoma
027		E-09	Natthaya	Chuaypen	Thailand	Circulating Mir-122 Levels At Baseline Predict Overall Survival Of Patients With Hepatocellular Carcinoma Treated With Transarterial Chemoembolization
028	Gut Liver Axis and Microbiome	F-02	Han	Wang	China	Observation of the clinical features of bacterial liver abscess with endogenous endophthalmitis
029		F-03	Rajendra	Patel	India	Prevalence And Predictive Factors Of Small Intestinal Bacterial Overgrowth (SIBO) In Patients With Cirrhosis Of Liver
030		F-04	Thananya	Jinato	Thailand	The alteration of gut microbiota composition in patients with hepatitis C virus (HCV) monoinfection and human immunodeficiency virus (HIV) coinfection.
031	Health Services Research	G-02	Pakanat	Decharatanachart	Thailand	Application of Artificial Intelligence in Chronic Liver Diseases: A Systematic Review and Meta-analysis
032		G-03	Glaiza	Ranges	Philippines	Assessment of the Quality of Life of Chronic Liver Disease Patients using the Filipino Versions of CLDQ and HADS
033		G-05	William Chi W	WONG	Hong Kong	Crowdsourcing to Promote Hepatitis C Testing and Linkage-to-care in China: Randomized Controlled Trial Interim report
034		G-06	Jalpa	Devi	Pakistan	Lower GI Endoscopy-Indications and findings in a Tertiary Care Hospital
035		G-07	Chee-Kiat	Tan	Singapore	Public Awareness and Knowledge on Liver Disease and Liver Health in Singapore
036		G-09	Daniel	Burkholder	United States	Specificity and Positive Predictive Value of International Classification of Diseases - 10 Diagnosis Codes for Cirrhosis
037		G-11	Rosmawati	Mohamed	Malaysia	Understanding the Knowledge, Attitudes and Practices of the Public towards Liver Disease in Malaysia
038		G-12	Jalpa	Devi	Pakistan	Upper GI Endoscopy-Indications and findings in a Tertiary Care Hospital
039		G-13	Rifaldy	Fajar	Indonesia	Diagnosis of Liver Disease based on Artificial Intelligence Systems using the Decision Tree Algorithm Implementation
040		G-14	Grace Lai-Hun	Wong	Hong Kong	Deep learning of CT images in patients with chronic viral hepatitis – a territory-wide study with data from HADCL from year 2000 to 2017
041		G-15	Young-Suk	Lim	South Korea	Impact of Expanding Antiviral Treatment Criteria at a Population Level in the Republic of Korea: A modeling analysis
042		G-16	Saurabh	Gaur	India	Crush Smear Cytology - An Adjunct To Biopsy In Gastrointestinal Malignancies
043		G-17	Tiffany	Hensley-mcbain	United States	Point-of-Care Interactive Decision Support Tool Demonstrates Discordance Between Healthcare Practitioner Approaches and APASL Guideline Recommendations in the Management of HBV Infection

No	Theme	Paper Ref	First Name	Last Name	Country	Paper Title
044	Hepatitis B and Hepatitis D	H-01	Shalini	Sethi	United States	96-week Efficacy and Safety of Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Switch vs. Continued TDF Treatment among Virologically-suppressed Hepatitis B patients of Asian Ethnicity (AE)
045		H-02	Juan	Zhao	China	A real-world clinical study of lipid changes on TAF treatment in Chinese chronic hepatitis B patients with diabetes
046		H-03	Mariz	Asoy	Philippines	Novel Case of Chronic Hepatitis B Reactivation in a COVID-Confirmed 78-year-old Male: A Case Report
047	Hepatitis B and Hepatitis D	H-04	Heejoon	Jang	South Korea	Association of Aspirin with Hepatocellular Carcinoma in Patients with Chronic Hepatitis B with or without Cirrhosis
048		H-05	Urbano	Sbarigia	Belgium	A Literature Review of the Epidemiological and Long-term Clinical Burden of Chronic Hepatitis B (CHB) Infection in Asia-Pacific
049		H-07	Muhammad A	Qadeer	Pakistan	Characteristics of hepatitis D in young adults
050		H-08	Cheuk Fung	Yip	Hong Kong	Chronic hepatitis B does not increase the risk of adverse clinical outcomes in patients with COVID-19: a territory-wide cohort of 2,256 patients
051		H-09	Bogi	Wibowo	Indonesia	Comparison of HBV DNA Suppression and Renal Safety Profile in Chronic Hepatitis B Patients at Saiful Anwar Hospital Malang
052		H-12	Bogi	Wibowo	Indonesia	Duration of Denial-Acceptance of The Kübler-Ross Cycle in Patients After Diagnosed Hepatitis B
053		H-13	Hasmik	Ghazinyan	Armenia	Characteristics of the Oral Mucosa in Patients with Chronic Viral Hepatitis B
054		H-14	Huey-Ling	Chen	Taiwan	Comparable Maternal Viral Load Reduction in TAF or TDF-treated Pregnant Women for Preventing Maternal HBV Transmission
055		H-15	Eric	Chan	United Kingdom	Content Development of a New Self-stigma Patient-reported Outcome Instrument for Chronic Hepatitis B: A Qualitative Study In China
056		H-16	Lu	Junfeng	China	Early antiviral efficacy of tenofovir alafenamide in initial treatment of patients with chronic hepatitis B
057		H-17	Dong	Ji	China	Cost savings of the PAGE-B score in reducing hepatocellular carcinoma (HCC) surveillance in Chinese with chronic hepatitis B (CHB)-related cirrhosis
058		H-18	Ieland	Yee	United States	Efficacy and safety of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF) in Chronic Hepatitis B patients of Asian Ethnicity following 5-years of treatment
059		H-19	Riaz	Hussain	Pakistan	Efficacy of Pegylated Interferon-Alpha-2a in Chronic Hepatitis D Infected Patients. Experience from the Tertiary Care Hospital in Karachi.
060		H-20	Andreas	Jekle	United States	Excellent preclinical characteristics of ALG-000184, a prodrug of the HBV capsid assembly modulator ALG-001075
061		H-21	Chuqian	Zheng	China	HBx-mediated ETV4 facilitates hepatocellular carcinoma invasion and metastasis via up-regulating the Dishevelled-2
062		H-22	Jin	Youn	South Korea	High Viral Suppression and Improved Safety Profile of Tenofovir Alafenamide Relative to Tenofovir Disoproxil Fumarate in Chronic Hepatitis B Patients Treated for 5 Years
063		H-23	Vadim	Bichko	United States	In Vitro and In Vivo Antiviral Properties of GST-HG141, a Novel Hepatitis B Virus Capsid Assembly Modulator in Clinical Development

No	Theme	Paper Ref	First Name	Last Name	Country	Paper Title
064	Hepatitis B and Hepatitis D	H-24	Peng	Chen	China	Effectiveness and Safety of Tenofovir Alafenamide (Taf) in Nucleoside Analogue (Na) Treatment Naïve Patients with Chronic Hepatitis B (Chb) in China
065		H-25	Sneha	Gupta	United States	Pharmacokinetics of VIR-2218, an RNAi therapeutic for the treatment of HBV infection, in healthy volunteers
066		H-26	Vikrant	Gohil	United States	Preclinical Efficacy and Pharmacokinetics of ALG-010133, an S-Antigen Transport-inhibiting Oligonucleotide Polymer (STOPS™) for the Treatment of Chronic Hepatitis B (CHB)
067		H-27	Bibigul	Ilyassova	Kazakhstan	Prevalence of hepatitis delta virus genotypes among patients with chronic viral hepatitis B with a Delta agent in Kazakhstan
068		H-28	Taeang	Arai	Japan	Real-world Outcomes of Sequential Therapy with Tenofovir Alafenamide Following Long-term Entecavir
069		H-29	Hyun Woong	Lee	South Korea	Extremely rare risk of hepatocellular carcinoma after naturally and Nucleos(t)ide Analogue induced Hepatitis B Surface Antigen Seroclearance
070		H-30	Jin	Youn	South Korea	Safety and Efficacy of Tenofovir Alafenamide in Geriatric Patients with Chronic Hepatitis B: Experience from 4 Ongoing Phase 2 and Phase 3 Clinical Trials
071		H-31	Edward	Gane	New Zealand	Safety and pharmacokinetics of single ascending doses of ALG-000184, a Class II Capsid Assembly Modulator for the treatment of Chronic Hepatitis B, in healthy volunteers
072		H-32	Dong	Ji	China	Kinetics of HBsAg and ALT decline in nucleos(t)ide analogue treated HBV subjects
073		H-34	Grace Lai-Hun	Wong	Hong Kong	Secular trend of disease burden in patients with chronic viral hepatitis – a territory-wide study of 143,701 patients with data from HADCL in 2000-2018
074		H-36	Dong	Yan	China	Significance of switching from ETV to TAF for CHB patients with suboptimal response to ETV: A Retrospective Cohort Study
075		H-37	Erkin	Musabaev	Uzbekistan	Simplified test & treat protocols to eliminate HCV & HBV in Uzbekistan
076		H-38	Lajpat	Rai	Pakistan	Long-Term Renal Safety Of Tenofovir Disoproxil Fumarate In Chronic Hepatitis B Patients
077		H-39	Hery Djagat	Purnomo	Indonesia	Response to Antiviral Therapy of Naïve Chronic Hepatitis B Patients in Semarang, Indonesia : a real-case study
078		H-40	Eiichi	Ogawa	Japan	Sequential Therapy with Tenofovir Alafenamide (TAF) in Patients with Chronic Hepatitis B (CHB): An Interim Analysis of an Ongoing Multinational Prospective Study
079		H-41	Yan	Liang	Hong Kong	Sodium-glucose co-transporter 2 inhibitors reduce hepatocellular carcinoma incidence in diabetic patients with chronic hepatitis B
080		H-42	Dong	Ji	China	Switching from entecavir to tenofovir alafenamide for chronic hepatitis B patients with low-level viremia
081		H-43	Peng	Chen	China	Switching to Tenofovir Alafenamide (TAF) from Entecavir in Chinese Chronic Hepatitis B (CHB) Patients

No	Theme	Paper Ref	First Name	Last Name	Country	Paper Title
082	Hepatitis B and Hepatitis D	H-45	Guan Huei	Lee	Singapore	Evolution of full-length hepatitis B virus quasispecies in HBeAg-negative patients during spontaneous viral reactivation and remission
083		H-47	Ying	Han	China	The incidence of hepatocellular carcinoma in patients with hepatitis B cirrhosis during long-term antiviral therapy: A real world cohort study
084		H-49	Dian	Utami	Indonesia	Mother To Child Hepatitis B Virus Transmission: Analysis Of Toll-Like Receptor 2 (TLR2) Expression, HBsAg, HBeAg, ANTI-HBs, ANTI-HBc, And Hepatitis Virus DNA Identification
085		H-50	Shuyan	Chen	China	Comparison of Fibrosis Regression of Entecavir Alone or Combined with Pegylated Interferon Alpha2a in Patients with Chronic Hepatitis B
086		H-51	Natthaya	Chuaypen	Thailand	Characteristics Of Hcc Patients With 'HBsAg-negative And Hbcrag-positive' Profile Undergoing Tace
087		H-52	Natthaya	Chuaypen	Thailand	Single Nucleotide Polymorphisms of TRAIL Receptor 1 are Linked to the Risk of Hepatitis B Virus-Related Hepatocellular Carcinoma
088		H-53	Natthaya	Chuaypen	Thailand	Serum Hbcrag Levels Are Correlated With Intrahepatic Replication Activity In Patients With Hbeag-positive Chronic Hepatitis B
089		H-54	Natthaya	Chuaypen	Thailand	Serum Sulfatase-2 As A Novel Diagnostic And Prognostic Marker Of HBV-related Hepatocellular Carcinoma
090		H-55	Natthaya	Chuaypen	Thailand	Characterization of Serum HBV RNA Quantification in the Phases of Chronic Hepatitis B Infection
091		H-56	Xiaoyan	Fang	China	ALT flare predicts hepatocellular carcinoma among antiviral treated patients with chronic hepatitis B: a cross-country cohort study
092		H-57	Xun	Qi	China	Effect of Glycyrrhizin on fibrosis regression in chronic hepatitis B patients treated with Entecavir
093		H-61	Li	Xiaoke	China	The Chinese herbal TiaoGanBuXueJieDu formula inhibits HBV replication and HBV-related hepatoma cell proliferation
094		H-64	Jin	Hong	United States	ALG-020572, a next generation antisense oligonucleotide (ASO) with bridged nucleic acid chemistry, has a significantly improved preclinical profile
095		H-67	Bibigul	Ilyassova	Kazakhstan	Distribution of hepatitis B virus genotypes and subtypes in the general population of Kazakhstan
096		H-68	Yeni	Kim	South Korea	Correlations between non-invasive biomarkers and fibrosis scores in chronic hepatitis B patients treated with tenofovir disoproxil fumarate and tenofovir alafenamide in Phase 3 clinical trials
097		H-69	Yeni	Kim	South Korea	Impact of pre-treatment plasma HBV DNA levels on the rate of ALT normalization during antiviral therapy with TAF or TDF for CHB
098		H-70	Yeni	Kim	South Korea	Coadministration without or with food on the 96-week efficacy and safety of tenofovir alafenamide in virally suppressed chronic HBV patients switched from tenofovir disoproxil fumarate
099		H-71	Yeni	Kim	South Korea	Phase 3 Study Comparing Switching from TDF to TAF with Continued TDF Treatment in Virologically-suppressed Patients with CHB: Final Week 96 Efficacy and Safety Results
100		H-72	Yeni	Kim	South Korea	Safety and Efficacy of 24 Weeks Treatment with Oral TLR8 Agonist, Selgantolimod, in Viremic Adult Patients with Chronic Hepatitis B: A Phase 2 Study

No	Theme	Paper Ref	First Name	Last Name	Country	Paper Title
101	Hepatitis B and Hepatitis D	H-73	Yeni	Kim	South Korea	Safety and Efficacy of Switching to Tenofovir Alafenamide in Virally Suppressed Chronic Hepatitis B Patients with Hepatic Impairment: Week 48 Results from Phase 2 Study
102		H-75	Heather	Sevinsky	United States	AB-729, a GalNAc-siRNA, results in robust reductions of HBV DNA and HBsAg in subjects with chronic hepatitis B infection
103		H-76	Jin	Youn	South Korea	Characterization of Serologic Responses Following ALT Flares in >3000 CHB Patients Pooled from 5 Clinical Trials
104		H-78	Lung-Yi	Mak	Hong Kong	Role of serum M2BPGi levels in predicting persistence of advanced fibrosis in chronic hepatitis B virus infection
105	Hepatitis C	I-01	Chunlan	Zhang	China	A Real-World Study of Treatment of Sofosbuvir/Velpatasvir on Chronic hepatitis C in Guangdong Province of China
106		I-03	Shi	Weifeng	China	Comparison of the pharmacokinetic parameters of ASC18 tablets (ravidasvir and sofosbuvir fixed dose combination) with reference tablets (ravidasvir, sofosbuvir) for hepatitis treatment
107		I-04	Dong	Ji	China	DAAs and NAFLD are associated with increased incidence of Hepatocellular carcinoma in patients with chronic HCV infection after sustained virologic response: a prospective multi-center study
108		I-06	Feng	Liu	China	Dynamic fibrosis features in HCV post-treatment liver biopsies and its interpretation
109		I-08	Jianping	Li	China	Effectiveness and safety of sofosbuvir/velpatasvir ± ribavirin in the treatment of Chinese adults with chronic HCV infection
110		I-09	Natthaya	Chuaypen	Thailand	Molecular Epidemiology And Evidence Of Patient-to-patient Transmission Of Hepatitis C Virus Within Hemodialysis Units
111		I-10	Yuyong	Jiang	China	Retreatment of Hepatitis C Failed a NS5A-containing DAAs Regimen
112		I-11	Chung-Feng	Huang	Taiwan	Scaling up in-hospital HCV care cascade in a medical center in Taiwan
113		I-12	Apichaya	Khlaiphuengsin	Thailand	Successful Direct-Acting Antiviral Therapy Improves Circulating Mucosal-Associated Invariant T Cells In Patients With Chronic HCV Infection
114		I-13	Tanat	Yongpisarn	Thailand	Systematic Review with Meta-analysis: Non-invasive assessment of liver fibrosis for the prediction of liver-related outcomes in chronic viral hepatitis C patients
115		I-14	Lichang	Chen	China	The Effectiveness of DAAs Treatment in Patients with Chronic Hepatitis C : A Multicenter, Prospective, Observational, Real-world Study in East China
116		I-15	Ching-i	Huang	Taiwan	The Fibrosis Characters of Hepatitis C Patients in Community.
117		I-16	Maneerat	Chayanupatkul	Thailand	The Role of Hepatitis C Virus Core Antigen in the Determination of Treatment Response after Direct Acting Anti-viral Agents.
118		I-17	Alver	Prasetya	Indonesia	The Safety and Efficacy of Direct-Acting Antivirals in HCV and HCV/HIV Patients with Blood Coagulation Disorders: A Systematic Review
119		I-18	Ming-Lung	Yu	Taiwan	Impact of Sofosbuvir-based direct-acting antivirals on renal function in chronic hepatitis C patients - a large cohort study from the nationwide HCV Registry Program (TACR)

No	Theme	Paper Ref	First Name	Last Name	Country	Paper Title
120	Hepatitis C	I-19	Riaz	Hussain	Pakistan	Treatment Outcomes Of Sofosbuvir And Velpatasvir In Chronic Hepatitis C Patients Undergoing Hemodialysis.
121		I-20	Yeni	Kim	South Korea	Long term follow-up of safety and efficacy of sofosbuvir-based HCV DAAs in pediatric patients
122		I-21	Toshifumi	Tada	Japan	Real-world virological efficacy and safety of ledipasvir and sofosbuvir in patients with chronic hepatitis C virus genotype 2 infection in Japan: a multicenter study
123		I-22	Yeni	Kim	South Korea	Risk of end-stage renal disease among hepatitis C patients with chronic kidney disease treated with and without sofosbuvir
124		I-24	Nyein Mon	Yu	Myanmar	Hepatitis C Genotype 3 subtypes and Y93H mutation in single center experience in Myanmar
125		I-25	Rattanaorn	Kiatbumrung	Thailand	The Association of PNPLA3, COX-2 and DHCR7 Polymorphisms with Advanced Liver Fibrosis in Patients with HCV Mono- Infection and HCV/HIV Co-Infection
126		I-26	Fanpu	Ji	China	Treatment outcome with DAAs in a multinational cohort of 11,099 hepatitis C (HCV) patients with genotypes 1, 2, 3, 4 and 6: A REAL-C study
127		I-27	Jee-Fu	Huang	Taiwan	Significant amelioration of hepatitis C virus infection in a hyper-endemic area: Longitudinal evidence from the COMPACT Study in Taiwan
128	Hepatobiliary Neoplasia	J-02	Osamu	Tanaka	Japan	99m-Tc-Technetium Galactosyl Human Serum Albumin Scanning to Evaluate Liver Function After Stereotactic Body Radiotherapy for Hepatocellular Carcinoma: A Case Report
129		J-03	Kittipitch	Bannangkoon	Thailand	ABO Blood Group Differential on the Survival in Hepatocellular Carcinoma Patient Treated with Chemoembolization
130		J-04	Usama	Abdelkader	Egypt	Are Vitamin D Receptor Polymorphisms Associated with a Risk of Hepatocellular Carcinoma in Hepatitis C Related Liver Cirrhosis?
131		J-06	Thiyaphat	Laohawetwanit	Thailand	Combined hepatocellular-cholangiocarcinoma and its mimickers: diagnostic pitfalls in surgical pathology
132		J-10	Ying	Han	China	Evaluation of the differential diagnosis value of PIVKA-II in patients with liver disease
133		J-11	Thodsawit	Tiyarattanachai	Thailand	Development and validation of artificial intelligence to detect and diagnose liver lesions from ultrasound images
134		J-13	Tetsuhiro	Chiba	Japan	FGF19/FGFR4 Signaling in Hepatocellular Carcinoma
135		J-14	Hasmik	Ghazinyan	Armenia	Hepatocellular carcinoma emergence in Armenia: Outcome of multiple risk factors for the period January 2019 to March 2020, Nork Clinical Hospital of Infectious Diseases
136		J-15	Sreedhara	Chaluvashetty	India	Image-guided Locoregional Therapies in the Management of HCC
137		J-16	Eiichiro	Suzuki	Japan	Impact of liver cirrhosis in patients with intrahepatic cholangiocarcinoma receiving systemic chemotherapy: a subgroup analysis of the JCOG1113 randomized phase III trial
138		J-17	Kazufumi	Kobayashi	Japan	Impact of multi molecular target agent therapy in advanced hepatocellular carcinoma
139	Hepatobiliary Neoplasia	J-18	Thiyaphat	Laohawetwanit	Thailand	Interpretation pitfalls in immunohistochemistry of primary liver carcinoma: a retrospective analysis of liver biopsy specimens
140		J-19	Robert	O'Neill	Australia	Massive hepatomegaly and abdominal pain – An unexpected presentation of primary choroidal melanoma
141		J-20	Sangdao	Boonkaya	Thailand	Outcomes of Patients with Advanced Stage Hepatocellular Carcinoma (HCC) Receiving Different Treatment Modalities: Real-World Data

No	Theme	Paper Ref	First Name	Last Name	Country	Paper Title
142	Hepatobiliary Neoplasia	J-21	Keisuke	Koroki	Japan	Posttreatment after Lenvatinib in Patients with Advanced Hepatocellular Carcinoma
143		J-22	I-ting	Liu	Taiwan	Predict Early Recurrence of Hepatocellular Carcinoma Using Multi-dimensional Artificial Intelligence Analysis of Liver Fibrosis
144		J-24	Takashi	Iizumi	Japan	Proton beam therapy for hepatocellular carcinoma with bile duct invasion
145		J-26	Tongluk	Teerasartiphan	Thailand	Risk factors of cholangiocarcinoma in non-endemic area of liver fluke infection
146		J-32	Ashok	Raj	New Zealand	The prevalence of palliative presentation for HCC over 10 years in a Maori, Pasifika and Asian cohort
147		J-34	thanikan	Sukaram	Thailand	Volatile organic compounds as potential biomarkers for diagnosis of hepatocellular carcinoma (HCC)
148		J-35	Jaejun	Lee	South Korea	Comparison of Lenvatinib versus Hepatic Arterial Infusion Chemotherapy for Unresectable Hepatocellular Carcinoma.
149		J-36	Natthaya	Chuaypen	Thailand	Diagnostic Performance Of PIVKA-II And AFP In Relation To Underlying Etiological Factors Of Hepatocellular Carcinoma
150		J-37	Margaret LP	Teng	Singapore	Complication Rates, Overall And Recurrence-Free Survival After Surgical Resection With Curative Intent For Hepatocellular Carcinoma: A Meta-Analysis Of 110 Studies And 82,392 Patients
151		J-39	Qing	Li	China	HIF-1 α -induced expression of m6A reader YTHDF1 drives hypoxia-induced autophagy and malignancy of hepatocellular carcinoma by promoting ATG2A and ATG14 translation
152		J-40	Qing	Li	China	Kinesin family member 15 promotes cancer stem cell phenotype and malignancy via reactive oxygen species imbalance in hepatocellular carcinoma
153		J-41	Minseok Albert	Kim	South Korea	Yttrium-90 Radioembolization Is Associated with Better Overall Survival in Patients with Hepatocellular Carcinoma Compared with Conventional Chemoembolization: A Propensity Score-Matched Study
154		J-42	Yoonseok	Lee	South Korea	Development of hand foot skin reaction is associated with good prognosis for HCC patients treated with Sorafenib ; A prospective cohort study
155		J-43	Qing	Li	China	Thymidine kinase 1 drives the malignancy and immunosuppression by regulating the PRMT1/YAP axis in Hepatocellular carcinoma
156		J-44	Erlangga	Arifin	Indonesia	The Efficacy of Lapatinib as a Safer Therapeutic Agent in Hepatocellular Carcinoma Patients: A Systematic Review
157	Hepatobiliary Surgery	K-02	Hendra	Koncoro	Indonesia	Multiple Gallstones And Bile Duct Stones In Chronic Myelogenous Leukemia
158		K-04	Jiangdong	Qiu	China	Somatostatin prevents clinically relevant pancreatic fistula in intermediate risk patients after pancreaticoduodenectomy (SPEED): a multi-center, randomized, controlled study
159	Hepatotoxicity	L-01	Stephanie	Johanes	Indonesia	Alpha-Methyldopa Induced Hepatotoxicity In Women With Hypertensive Disorders Of Pregnancy: A Systematic Review Of Case Reports
160		L-02	Lajpat	Rai	Pakistan	Covid 19 Associated Liver Injury: Clinical Manifestations, Challenges And Outcome: A Real Life Experience From Pakistan
161		L-03	Meenal	Patwardhan	United States	Drug- Induced Liver Injury in the Elderly – Do We Know What We Don't Know?
162		L-04	Rivaldi	Ruby	Indonesia	Hepatoprotectants Efficacy Against Anti-Tuberculosis Drug-Induced Liver Injury: A Systematic Review Of Randomized Controlled Trial
163		L-06	Stephanie	Johanes	Indonesia	Remdesivir Associated Acute Liver Injury In Covid-19 Patients: A Case Based Systematic Review
164		L-07	Abeer	Altaf	Pakistan	Severity Of Covid-19 Is Associated With Liver Injury In Patients Without Pre-Existing Liver Disease

No	Theme	Paper Ref	First Name	Last Name	Country	Paper Title
165	Hepatotoxicity	L-08	Mithun Harold	Thomas	India	Statin Related Drug Induced Liver Injury: A Case Series
166		L-10	Hyun	Yang	South Korea	Intrahepatic infiltration of activated CD8+ T cells and macrophages is associated with the severity of liver injury in drug-induced liver injury: implications in steroid therapy
167		L-11	Parimita	Barua	India	To Study LFT Abnormality in Patients with Ischemic Hepatitis and Congestive Hepatopathy and 7 Days Predictor Of Mortality.
168		L-12	Abhasnee	Sobhonslidsuk	Thailand	Drug-induced liver injury registry and the study of factors associated with its clinical course: a multicenter study
169	Human Cholestatic and Autoimmune Liver Diseases	M-02	Ying	Han	China	Establishing a non-invasive diagnosis model of liver cirrhosis in patients with primary biliary cholangitis based on the liver disease research database
170		M-04	Alver	Prasetya	Indonesia	The Potential of Soluble Programmed Cell Death Protein-1 (sPD-1) and Anti-PD-1 as Serological Markers of Autoimmune Hepatitis: A Systematic Review
171		M-05	Kim	Vaiphei	India	Two autopsy cases with rare aetiologies for massive hepatomegaly in middle aged females
172		M-06	Chunpan	Zhang	China	Double negative T cells therapy alone or in combination with oral UDCA alleviates primary biliary cholangitis in mice
173	Inflammation and Immunobiology	N-01	Arnab	Dey	India	A Prospective Case Control Study Of Liver Dysfunction In Hyperthyroidism With Special Reference To Portal Venous Flow And Fibrosis Assesement And Its Reversal Following Treatment
174		N-04	ASTUSHI	NAKAMURA	Japan	Impact of Systemic Inflammation on Liver Function as Assessed by ALBI Grade
175		N-05	Pil Soo	Sung	South Korea	Expression analysis by Nanostring nCounter system in non-alcoholic steatohepatitis identifies activated macrophages as key mediators of inflammation
176		N-06	Pil Soo	Sung	South Korea	Inflammation-induced, IgA (+) PD-L1-high tumor-associated macrophages are the main targets of immune checkpoint inhibitors in hepatocellular carcinoma
177	Liver Fibrogenesis and Non-Parenchymal Cell Biology	O-01	Olga	Tarasova	Russian Federation	EPR-TSA method for the diagnosis of liver fibrosis
178		O-02	Xudong	Hu	China	Fuzhenghuayu recipe alleviates DMN-induced mice liver fibrosis through regulating recruitment and phenotype polarization of Bone marrow-derived macrophages
179		O-05	Xiya	Lu	China	miR-30d Alleviates Liver Fibrosis through Inhibiting Hepatic Stellate Cell Activation
180		O-06	Ryota	Masuzaki	Japan	Small surgical incisions in the liver cause fibrotic response in adult and neonatal mice.
181		T-05	Xingshun	Qi	China	Liver Biochemical Abnormality and In-hospital Outcome in COVID-19 Patients with Liver Cirrhosis
182		P-04	Ken	Liu	Australia	Impact of intensive care unit discharge delay on outcomes after liver transplantation
183		P-06	Stephanie	Johanes	Indonesia	Low Birth Weight And Preterm Delivery In Pregnancies Following A Liver Transplant: A Systematic Review Of Retrospective Cohort Studies
184		P-08	Stephanie	Johanes	Indonesia	The Role Of Qt Prolongation And Nt-Probnp To Predict Mortality In Liver Transplant Patient: A Systematic Review And Meta Analysis
185		P-09	Jalpa	Devi	Pakistan	Trends in Etiology of Chronic Liver Disease referred for Liver Transplant evaluation in Pakistan 2020

No	Theme	Paper Ref	First Name	Last Name	Country	Paper Title
186	NAFLD and NASH	Q-03	Jee-Fu	Huang	Taiwan	A Double-Blind, Randomized, Placebo-Controlled, Phase II Study to Assess the Efficacy and Safety of Pioglitazone in Taiwanese Patients with Nonalcoholic Steatohepatitis
187		Q-04	Umida	Usmanova	Uzbekistan	A New Method For Early Diagnostics Of Obesity In Non-Alcoholic Fatty Liver Disease
188		Q-07	Jenny	Chu	Hong Kong	Association Between Chronic Hepatitis B And Human Immunodeficiency Virus Infection With Hepatic Steatosis And Fibrosis By Non-invasive Assessment
189		Q-08	Hsiu Ping	Lin	Taiwan	BioFibroScore®: a new non-invasive method for diagnosing hepatic fibrosis in NAFLD and NASH
190		Q-09	Ajay	Duseja	India	Changing Clinicopathological Profile Of Nonalcoholic Fatty Liver Disease In India - Interim Results Of The Icon-d (Indian Consortium On Nafld) Study
191	NAFLD and NASH	Q-10	Ajay	Duseja	India	Clinical Outcomes In A Real-world Cohort Of Patients With Non-alcoholic Fatty Liver Disease In South Asia
192		Q-14	Satyendra K	Tyagi	India	Efficacy of saroglitazar in non- alcoholic fatty liver disease using real world clinically relevant non- invasive parameters
193		Q-15	Erlangga	Arifin	Indonesia	Empagliflozin Effect of Reducing Liver Fat in NAFLD Patients with DM type 2: A Systematic Review of a Potent Therapeutic Agent
194		Q-19	Elijah	Weber	United States	Japanese subjects have moderately higher plasma exposures of the acetyl CoA carboxylase (ACC) inhibitor firsocostat (FIR) than Caucasian subjects
195		Q-20	Elijah	Weber	United States	Lack of Clinically Meaningful Differences in Pharmacokinetics and Pharmacodynamics of the FXR agonist Cifofexor in Japanese and Caucasian Participants
196		Q-23	Olga	Tarasova	Russian Federation	New Possibilities Of Saliva Investigation For Diagnosis Of Steatohepatitis
197		Q-30	Gregor	Weber	United States	Safety and efficacy of combination therapies including semaglutide, cifofexor, and firsocostat in patients with NASH
198		Q-31	Xinrong	Zhang	Hong Kong	Screening Colonoscopy and Colorectal Cancer Incidence in Patients with Non-Alcoholic Fatty Liver Disease: A Retrospective Cohort Study
199		Q-32	Grit	Andersen	Germany	Semaglutide Treatment in Subjects with Nafld: Effects Assessed by Magnetic Resonance Elastography and Magnetic Resonance Imaging Proton Density Fat Fraction
200		Q-33	Kotchakon	Maipang	Thailand	Significant Liver Fibrosis is Associated with Increased Risk of Advanced Adenoma in Average-Risk Population with Metabolic Associated Fatty Liver Disease
201		Q-35	Wei-Yu	Kao	Taiwan	The plasma and liver triglyceride subclass of nonalcoholic steatohepatitis and fibrosis in morbidly obese patients
202		Q-36	Jenny	Norlin	Denmark	Triple combination therapy of GLP-1 receptor agonist semaglutide with an FXR agonist and ACC inhibitor reverses non-alcoholic steatohepatitis (NASH) in diet-induced and biopsy-confirmed mice
203		Q-37	Soo Min	Bang	South Korea	Diagnosis of Nonalcoholic Steatohepatitis with Mr-based Nonalcoholic Steatohepatitis Score
204		Q-38	Soo Min	Bang	South Korea	Serum Mirna as a Useful Diagnostic Biomarker for Non-alcoholic Steatohepatitis and a Predictor for Disease Progression in Patients with Non-alcoholic Fatty Liver Disease
205		Q-39	Li	Changying	China	The Proportions and Functions of CD4-CD8- Double Negative T Cells during Non-alcoholic Fatty Liver Disease Development
206		Q-41	Thaninee	Prasoppokakorn	Thailand	Validation Model of FIB-8 Score to Predict Significant Fibrosis Among Patients with Non-alcoholic Fatty Liver Disease
207		Q-43	Zijian	Zhang	China	Development and validation of a robust predictor for the carcinogenesis potential of non-alcoholic steatohepatitis patients: NASH-related Carcinogenesis Score (The NASH-C Score)

No	Theme	Paper Ref	First Name	Last Name	Country	Paper Title
208	Other Viral Hepatitis	R-03	Wenyu	Wu	China	Clinical characteristics and risk factors of liver injury in COVID-19: a retrospective cohort study from Wuhan, China
209		R-04	Damodar	Krishnan	India	Clinical profile and factors influencing mortality of patients diagnosed with acute Hepatitis E in a tertiary center in South India
210		R-12	Narisara	Tribuddharat	Thailand	Incidence and characteristic of Dengue hemorrhagic fever with severe hepatitis
211		R-13	Tatsuo	Kanda	Japan	Inhibitory effects of zinc chloride on hepatitis A virus replication through the cytokines in hepatocytes
212		R-18	Hideo	Yoshida	Japan	SARS-cov2 infection and liver dysfunction
213		R-19	Tatsuo	Kanda	Japan	Screening for inhibitors of hepatitis A virus internal ribosomal entry site and HAV replication
214	Pediatric Hepatology	S-01	Patcharin	Amornvipas	Thailand	A Thai Girl Fever with Hepatosplenomegaly and Liver Cyst
215		S-07	Chatmanee	Lertudomphonwar	Thailand	Prevalence And Long-Term Outcome Of De Novo Hepatitis B Infection In Pediatric Liver Transplant Recipients
216		S-08	Chatmanee	Lertudomphonwar	Thailand	Low Psoas Muscle Index As An Unfavorable Factor In Children With End-Stage Liver Disease Undergoing Liver Transplantation
217	Portal Hypertension and Other Complications of Cirrhosis	T-02	Ellaine	Wei-munji	Philippines	A Comparative Study on the Diagnostic Accuracy of Non-Invasive Scoring Tests in detecting Esophageal Varices in patients with Liver Cirrhosis – A Retrospective Study
218		T-03	Yu	Tian	China	A status survey of albumin infusion and its relationship with prognosis in cirrhotic patients with ascites in China
219		T-06	Xingshun	Qi	China	Adherence to Non-Selective Beta Blockers in Cirrhotic Patients with Esophageal Varices
220		T-07	Adinda	Rahadini	Indonesia	Anticoagulant Therapy for Cirrhosis-related Portal Vein Thrombosis: A Meta-Analysis
221		T-13	Peng	Zhu	China	Clinical value of liver stiffness measurement combined with spleen stiffness measurement for predicting esophageal-gastric varices in patients with cirrhosis
222		T-14	Rivaldi	Ruby	Indonesia	Comparative Analysis On Efficacy Of Losartan Versus Propranolol As Portal Pressure Reduction Therapy In Cirrhotic Patients With Portal Hypertension: A Systematic Review Of Randomized Controlled Trial
223		T-15	Aleksandra	Bodys-Pelka	Poland	Alterations in the Cardiovascular System in Patients with Cirrhosis - Assessment of a Haemodynamic Profile.
224		T-16	Napapong	Nitiwarangoon	Thailand	Difference in Characteristics and Clinical Outcomes among Six Organ Failures of Cirrhotic Patients Hospitalized with an Acute Decompensation with and without Acute-on-Chronic Liver Failure (ACLF)
225		T-17	Mithun Harol	Thomas	India	Elevated Serum Ferritin And CRP Levels As Prognostic Markers In Decompensated Cirrhosis: A Prospective Cohort Study
226		T-19	Ksheetij	Kothari	India	Endoscopic Management of Portal Cavernoma Cholangiopathy: A Single Center Experience

No	Theme	Paper Ref	First Name	Last Name	Country	Paper Title
227	Portal Hypertension and Other Complications of Cirrhosis	T-20	Koki	Nagai	Japan	Gastroesophageal varices evaluation using a novel spleen-dedicated stiffness measurement by Fibroscan
228		T-21	Jalpa	Devi	Pakistan	Is It Necessary To Transfuse FFP And Platelets Before Band Ligation in Acute Variceal Bleeding Patients? South East Asia Experience. RIP FFP And Platelets Transfusion!
229		T-25	Xingshun	Qi	China	Natural history and predictors associated with the evolution of portal venous system thrombosis in liver cirrhosis
230		T-26	Xingshun	Qi	China	No association of homocysteine, anticardiolipin antibody, and anti-β2 glycoprotein I antibody with portal venous system thrombosis in liver cirrhosis
231		T-28	Jeong Han	Kim	South Korea	One month and three month readmission rates in cirrhotic patients were not changed during past seven years
232		T-29	Xingshun	Qi	China	Outcomes of early versus delayed endoscopy in cirrhotic patients with acute variceal bleeding: A systematic review and meta-analysis
233		T-31	Xingshun	Qi	China	Portal venous system thrombosis after bariatric surgery: A systematic review and meta-analysis
234		T-33	Haryono	Haryono	Indonesia	Prediction of Esophageal Varices Grading in Cirrhotic Patients using Liaoning, Albumin-Bilirubin and Platelets-Albumin-Bilirubin Score
235		T-34	Adinda	Rahadini	Indonesia	Presence of Atrial Fibrillation is Associated with Increased Mortality Risk in Cirrhosis Patients: Meta Analysis
236		T-35	Kessarini	Thanapirom	Thailand	Prevalence, characteristics and prognosis of bacterial infection in patients with decompensated cirrhosis and acute-on-chronic liver failure: a multi-center study
237		T-36	Arunchai	Chang	Thailand	Role of Lactulose for Prophylaxis on Hepatic Encephalopathy in Cirrhotic Patient Presented with Upper Gastric Intestinal Bleeding
238		T-38	Neeraj	Singla	India	SARC-F score: A quick bedside questionnaire to assess sarcopenia in Cirrhosis
239		T-39	Xingshun	Qi	China	Spontaneous splenorenal shunt may decrease the long-term survival of liver cirrhosis by compromising liver volume
240		T-41	Bogi	Wibowo	Indonesia	The Association Between Hepatic Cirrhosis Complications and Total Lymphocyte Count in Hepatic Cirrhosis Patients at Saiful Anwar Hospital Malang
241		T-42	Ahmad Fariz N	Zein	Indonesia	The clinical profiles and in-hospital clinical outcome in young adult patients with esophageal varices: one-year observation
242		T-43	Manami	Yoshida	Japan	The Effectiveness Of Oral Thrombopoietin Receptor Agonist, Lusutrombopag For The Treatment Of Thrombocytopenia In Chronic Liver Disease Patients Undergoing Invasive Procedure In Japan.
243		T-46	Peng	Chen	China	The Value of Platelet Parameters and Related Scoring System in Predicting Esophageal Varices and Collateral Veins in Patients with Liver Cirrhosis
244		T-47	Jalpa	Devi	Pakistan	Thirty-Day Readmission after Esophageal Variceal Hemorrhage and Its Impact on Outcomes in the Tertiary care Hospital
245		T-48	Dipen	Agrawal	India	To Study the Prevalence of Hepato-Adrenal Syndrome & Low HDL Value<40 mg/dl in Hemodynamically Stable Liver Cirrhotic Patients

No	Theme	Paper Ref	First Name	Last Name	Country	Paper Title
246	Portal Hypertension and Other Complications of Cirrhosis	T-49	Dipen	Agrawal	India	To Study The Prevalence Of Hepato-Adrenal Syndrome In Hemodynamically Stable Liver Cirrhotic patients
247		T-51	Rattaya	Janyajirawong	Thailand	Efficacy of zinc supplement in minimal hepatic encephalopathy : A prospective, randomized controlled trial
248		T-52	Keerati	Kiattikunrat	Thailand	The Impact Of Frailty On Decompensation And Survival In Patients With Cirrhosis: A Prospective Cohort Study
249		T-53	Hyung Jun	Kim	South Korea	Repeated versus Single Treatment of Esophageal Variceal Ligation after Esophageal Variceal Bleeding: Multicenter Retrospective Study
250		T-54	Rohit	Mehtani	India	Hepatic Encephalopathy in ACLF – Is intravenous BCAA the answer? Interim analysis of the BCAA-ACLF Trial
251		T-55	Rohit	Mehtani	India	Utility of Bispectral Index for objective assessment of Hepatic Encephalopathy in Acute on Chronic Liver Failure
252		T-56	Padmanabhan	Purushothaman	India	Platelets In Chronic Liver Disease: Beyond Numbers...
253		T-57	Hae Won	Yoo	South Korea	The prediction of liver decompensation using hepatic collagen deposition assessed by computer-assisted image analysis with Masson-trichrome stain
254	Training and Education (Career Development)	U-01	Muhammad A	Qadeer	Pakistan	Assessing the knowledge of trainee residents for liver involvement and related issues in COVID-19 pandemic.
255		U-04	Sureeporn	Jangsirikul	Thailand	Video-assisted Liver Ultrasound Training for Non-radiologists